Reflections on Black Women with HIV and Incarceration
Blog updated 11/29/2022
Blog updated 11/29/2022
Resource from the RWHAP Best Practices Compilation updated on 01/03/2024
Resource from the RWHAP Best Practices Compilation updated on 01/03/2024
Resource updated 01/08/2024
Resource updated 03/04/2024
Blog updated 06/30/2022
Resource from the RWHAP Best Practices Compilation updated on 01/07/2024
Resource from the RWHAP Best Practices Compilation updated on 01/03/2024
Resource updated 06/09/2022
Resource updated 01/05/2024
Resource from the RWHAP Best Practices Compilation updated on 11/27/2023
Resource updated 09/19/2023
Resource from the RWHAP Best Practices Compilation updated on 02/28/2024
Resource updated 09/19/2023
Resource updated 01/08/2024
The syndemic of opioid use disorder, HCV and HIV and stigma causes burdens on individuals and the system. Integrating siloed systems of care is critical to addressing this crisis. Overlapping cascades of care are key to understanding the empirical relationships of these diseases and opportunities to identify, prevent and co-treat.
Resource (Conference Presentation) updated 09/14/2023
California’s AIDS Drug Assistance Program (ADAP) and Pre-Exposure Prophylaxis Assistance Program (PrEP-AP) provide access to life-saving medications and insurance assistance for eligible California residents living with or at risk of acquiring HIV. This presentation will explore the efficacy of various program policy changes implemented by California during the COVID-19 pandemic.
Resource (Conference Presentation) updated 09/14/2023
After language-specific outreach on getting a COVID-19 vaccination, project saw a high rate of vaccine uptake in Spanish-speaking patients (81%) compared to English-speaking patients (4%).
Resource (Conference Presentation) updated 09/14/2023
NASTAD’s National AIDS Drug Assistance Program (ADAP) Formulary Database provides an online, searchable, publicly available resource detailing state-by-state ADAP coverage of medications, including HIV antiretroviral (ARV) treatments, “A1” Opportunistic Infections (A1 OI) medications, treatments for hepatitis B and C, mental health and substance use treatment medications, and various vaccines and laboratory tests.
Resource updated 03/07/2024